A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

NCT00161564 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Idiopathic Thrombocytopenic Purpura (ITP)

Interventions

DRUG: Rituximab

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]